ONVO vs. BCDA, IKT, GENE, SRNE, COEP, MBOT, TTNP, CELZ, SNTI, and CHRO
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include BioCardia (BCDA), Inhibikase Therapeutics (IKT), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Coeptis Therapeutics (COEP), Microbot Medical (MBOT), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Senti Biosciences (SNTI), and Chromocell Therapeutics (CHRO). These companies are all part of the "medical" sector.
BioCardia (NASDAQ:BCDA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.
BioCardia has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
20.6% of BioCardia shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 23.9% of BioCardia shares are held by insiders. Comparatively, 5.0% of Organovo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, BioCardia had 1 more articles in the media than Organovo. MarketBeat recorded 2 mentions for BioCardia and 1 mentions for Organovo. Organovo's average media sentiment score of 0.50 beat BioCardia's score of 0.36 indicating that BioCardia is being referred to more favorably in the media.
Organovo received 186 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 50.65% of users gave Organovo an outperform vote while only 47.62% of users gave BioCardia an outperform vote.
Organovo has a net margin of 0.00% compared to Organovo's net margin of -2,425.79%. BioCardia's return on equity of -182.88% beat Organovo's return on equity.
BioCardia currently has a consensus target price of $4.00, indicating a potential upside of 962.13%. Given Organovo's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than Organovo.
BioCardia has higher revenue and earnings than Organovo. BioCardia is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Summary
BioCardia beats Organovo on 10 of the 17 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
